title: Preservative-free bimatoprost 0.03%/timolol 0.5% fixed combination in patients with glaucoma in clinical practice.
abstract: OBJECTIVE
  The aim of this study was to evaluate the efficacy and tolerability of, and compliance to, preservative-free (PF), fixed-combination (FC) bimatoprost 0.03%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension in a clinical practice setting.
  
  
  METHODS
  This open-label study observed patients switched to PF FC bimatoprost 0.03%/timolol 0.5% due to insufficient intraocular pressure (IOP) control on previous therapies. IOP was measured at baseline and at ~12 weeks. Tolerability and continuation of therapy were also assessed.
  
  
  RESULTS
  A total of 1,553 patients were included in the study, and the per-protocol population comprised 1,391 patients. There were some minor deviations from protocol: some patients with no prior therapy and some who switched for reasons other than insufficient IOP control were included in the analysis. The mean IOP was reduced by 27.4%, from 22.2 mmHg to 16.1 mmHg. In subgroup analyses, the mean IOP was significantly reduced from baseline, irrespective of whether previous treatment was monotherapy or combination therapy, and preserved or PF therapy. Physicians mostly (88.1%) reported the IOP-lowering efficacy of PF FC bimatoprost 0.03%/timolol 0.5% to be as expected or better than expected. Switching to PF FC bimatoprost 0.03%/timolol 0.5% resulted in reductions from baseline in the number of patients reporting ocular symptoms. Adverse events were reported by 6.2% of patients, the most common being eye irritation (1.6%) and eye pruritus (1.0%). Physicians reported treatment compliance as better or unchanged compared with prior treatment in almost all patients (93.9%). Most patients were expected to continue PF FC bimatoprost 0.03%/timolol 0.5% after the end of the study.
  
  
  CONCLUSIONS
  Switching to PF FC bimatoprost 0.03%/timolol 0.5% was associated with significant IOP reductions from baseline over 12 weeks. Adverse events were uncommon, and compliance was high compared with previous therapy. PF FC bimatoprost 0.03%/timolol 0.5% may be a suitable treatment for patients with inadequately controlled IOP or who are sensitive to preservatives.
authors.affiliation: Polch Ophthalmology Practice, Polch.
authors.forename: Stefan
authors.initials: S
authors.lastname: Pfennigsdorf
authors.affiliation: Ophthalmology Practice, Kiel.
authors.forename: Peter
authors.initials: P
authors.lastname: Eschstruth
authors.affiliation: Ophthalmology Practice, Wiesloch.
authors.forename: Stefan
authors.initials: S
authors.lastname: Häsemeyer
authors.affiliation: Ophthalmology Practice, Lehrte.
authors.forename: Cord
authors.initials: C
authors.lastname: Feuerhake
authors.affiliation: Ophthalmology Practice, Dortmund, Germany.
authors.forename: Gerrett
authors.initials: G
authors.lastname: Brief
authors.affiliation: Allergan Holdings Ltd., Marlow, UK.
authors.forename: Ioana
authors.initials: I
authors.lastname: Grobeiu
authors.affiliation: Allergan Holdings Ltd., Marlow, UK.
authors.forename: Andrew
authors.initials: A
authors.lastname: Shirlaw
keywords: bimatoprost 0.03%/timolol 0.5%; fixed combination; glaucoma; intraocular pressure; preservative free; prostaglandin